Stock listing
KRX:002630 Orientbio, Inc. (오리엔트바이오) 주가
Follow Orientbio, Inc. into a list and get an email when it puts out news.
Share price · KRX:002630
₩1,136.00 KRW -26.00 (-2.2%)
Close on Nov 20, 2026
- Day range
- ₩1,136.00 – ₩1,179.00 KRWNov 20, 2026
- Volume
- 17,690 sharesNov 20, 2026
- Market cap
- ₩33.68B KRWAt the close on Nov 20, 2026 · price × 29.65M shares outstanding
- 52-week range
- ₩745.00 – ₩1,936.00 KRWLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₩87.71M KRWMedian day 46,115 shares · 2 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · KRX:002630 · KRW, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₩1,136.00 | -26.00 | -2.2% | ₩1,178.00 | ₩1,179.00 | ₩1,136.00 | 17,690 | |
| ₩1,162.00 | -27.00 | -2.3% | ₩1,188.00 | ₩1,245.00 | ₩1,074.00 | 85,854 | |
| ₩1,189.00 | -18.00 | -1.5% | ₩1,231.00 | ₩1,231.00 | ₩1,116.00 | 47,632 | |
| ₩1,207.00 | -70.00 | -5.5% | ₩1,277.00 | ₩1,286.00 | ₩1,200.00 | 121,047 | |
| ₩1,277.00 | +4.00 | +0.3% | ₩1,328.00 | ₩1,328.00 | ₩1,270.00 | 20,256 | |
| ₩1,273.00 | -13.00 | -1.0% | ₩1,273.00 | ₩1,390.00 | ₩1,260.00 | 63,801 | |
| ₩1,286.00 | -4.00 | -0.3% | ₩1,288.00 | ₩1,314.00 | ₩1,280.00 | 8,015 | |
| ₩1,290.00 | +15.00 | +1.2% | ₩1,276.00 | ₩1,297.00 | ₩1,273.00 | 24,528 | |
| ₩1,275.00 | -38.00 | -2.9% | ₩1,365.00 | ₩1,365.00 | ₩1,229.00 | 39,227 | |
| ₩1,313.00 | -50.00 | -3.7% | ₩1,229.00 | ₩1,352.00 | ₩1,229.00 | 57,436 | |
| ₩1,363.00 | +166.00 | +13.9% | ₩1,227.00 | ₩1,445.00 | ₩1,185.00 | 363,594 | |
| ₩1,197.00 | +23.00 | +2.0% | ₩1,190.00 | ₩1,221.00 | ₩1,177.00 | 21,064 | |
| ₩1,174.00 | -36.00 | -3.0% | ₩1,189.00 | ₩1,249.00 | ₩1,151.00 | 40,685 | |
| ₩1,210.00 | +20.00 | +1.7% | ₩1,222.00 | ₩1,225.00 | ₩1,155.00 | 15,786 | |
| ₩1,190.00 | -39.00 | -3.2% | ₩1,229.00 | ₩1,263.00 | ₩1,170.00 | 31,053 | |
| ₩1,229.00 | -59.00 | -4.6% | ₩1,250.00 | ₩1,300.00 | ₩1,209.00 | 44,959 | |
| ₩1,288.00 | -9.00 | -0.7% | ₩1,283.00 | ₩1,330.00 | ₩1,280.00 | 20,174 | |
| ₩1,297.00 | -26.00 | -2.0% | ₩1,270.00 | ₩1,329.00 | ₩1,269.00 | 46,115 | |
| ₩1,323.00 | -37.00 | -2.7% | ₩1,379.00 | ₩1,382.00 | ₩1,320.00 | 29,290 | |
| ₩1,360.00 | -19.00 | -1.4% | ₩1,379.00 | ₩1,379.00 | ₩1,346.00 | 18,604 | |
| ₩1,379.00 | -60.00 | -4.2% | ₩1,436.00 | ₩1,438.00 | ₩1,366.00 | 83,253 | |
| ₩1,439.00 | -37.00 | -2.5% | ₩1,435.00 | ₩1,485.00 | ₩1,431.00 | 48,276 | |
| ₩1,476.00 | -30.00 | -2.0% | ₩1,504.00 | ₩1,542.00 | ₩1,406.00 | 175,241 | |
| ₩1,506.00 | -2.00 | -0.1% | ₩1,450.00 | ₩1,519.00 | ₩1,450.00 | 29,334 | |
| ₩1,508.00 | -2.00 | -0.1% | ₩1,510.00 | ₩1,562.00 | ₩1,491.00 | 50,958 | |
| ₩1,510.00 | -85.00 | -5.3% | ₩1,575.00 | ₩1,579.00 | ₩1,502.00 | 42,256 | |
| ₩1,595.00 | +60.00 | +3.9% | ₩1,560.00 | ₩1,636.00 | ₩1,502.00 | 99,054 | |
| ₩1,535.00 | -67.00 | -4.2% | ₩1,510.00 | ₩1,586.00 | ₩1,494.00 | 145,301 | |
| ₩1,602.00 | -36.00 | -2.2% | ₩1,632.00 | ₩1,647.00 | ₩1,602.00 | 34,946 | |
| ₩1,638.00 | -21.00 | -1.3% | ₩1,690.00 | ₩1,690.00 | ₩1,631.00 | 19,401 | |
| ₩1,659.00 | -17.00 | -1.0% | ₩1,676.00 | ₩1,699.00 | ₩1,652.00 | 24,072 | |
| ₩1,676.00 | +36.00 | +2.2% | ₩1,668.00 | ₩1,718.00 | ₩1,630.00 | 26,374 | |
| ₩1,640.00 | +12.00 | +0.7% | ₩1,647.00 | ₩1,657.00 | ₩1,628.00 | 27,445 | |
| ₩1,628.00 | -14.00 | -0.9% | ₩1,611.00 | ₩1,668.00 | ₩1,611.00 | 50,565 | |
| ₩1,642.00 | -59.00 | -3.5% | ₩1,710.00 | ₩1,710.00 | ₩1,641.00 | 113,919 | |
| ₩1,701.00 | -92.00 | -5.1% | ₩1,793.00 | ₩1,793.00 | ₩1,685.00 | 78,882 | |
| ₩1,793.00 | -36.00 | -2.0% | ₩1,824.00 | ₩1,824.00 | ₩1,775.00 | 61,302 | |
| ₩1,829.00 | -26.00 | -1.4% | ₩1,813.00 | ₩1,867.00 | ₩1,813.00 | 33,231 | |
| ₩1,855.00 | +29.00 | +1.6% | ₩1,936.00 | ₩1,936.00 | ₩1,821.00 | 184,192 | |
| ₩1,826.00 | 0.00 | 0.0% | ₩1,826.00 | ₩1,826.00 | ₩1,826.00 | 0 | |
| ₩1,826.00 | +913.00 | +100.0% | ₩1,826.00 | ₩1,826.00 | ₩1,826.00 | 0 | |
| ₩913.00 | +73.00 | +8.7% | ₩840.00 | ₩923.00 | ₩810.00 | 378,301 | |
| ₩840.00 | -33.00 | -3.8% | ₩873.00 | ₩873.00 | ₩824.00 | 113,148 | |
| ₩873.00 | -6.00 | -0.7% | ₩860.00 | ₩874.00 | ₩850.00 | 65,853 | |
| ₩879.00 | -32.00 | -3.5% | ₩920.00 | ₩924.00 | ₩879.00 | 123,812 | |
| ₩911.00 | -11.00 | -1.2% | ₩930.00 | ₩949.00 | ₩906.00 | 44,279 | |
| ₩922.00 | -3.00 | -0.3% | ₩925.00 | ₩926.00 | ₩906.00 | 30,558 | |
| ₩925.00 | -12.00 | -1.3% | ₩937.00 | ₩944.00 | ₩900.00 | 56,509 | |
| ₩937.00 | +18.00 | +2.0% | ₩919.00 | ₩951.00 | ₩898.00 | 59,790 | |
| ₩919.00 | -24.00 | -2.5% | ₩930.00 | ₩936.00 | ₩917.00 | 50,830 | |
| ₩943.00 | -7.00 | -0.7% | ₩950.00 | ₩985.00 | ₩908.00 | 79,008 |
Splits
3 splits since 2003 · KRX:002630 · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-2 | Consolidation | |
| 1-for-2.245 | Consolidation | |
| 5-for-1 | Split |
- Ticker
- KRX:002630
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- KRX
- Currency
- KRW
What changed lately
Latest news release · Dec 2, 2025
Orient Bio To Sell 9.4 Billion Won Of Own Shares
Latest news
Orient Bio To Sell 9.4 Billion Won Of Own Shares
Dec 2, 2025
Closed ₩1,254.00 (-0.8%) on Dec 3, 2025
Orientbio, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 1 in the last 12 months · 1 in all · newest Dec 2, 2025 · oldest 2025
Valuation
P/E 14.6× against a median of 19.3×: 2nd lowest of 4 Diagnostics & research services companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −₩4.40B KRW
- P/E
- 14.6×
- EV/sales
- −0.1×
- EV/EBITDA
- −0.8×
- Price/book
- 0.5×
- Gross margin
- 22.6%
- Operating margin
- 9.9%
- Net margin
- 8.1%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Orientbio, Inc. · KRX:002630 | US$25.17M | −US$3.29M | 14.6× | −0.1× | −0.8× | 0.5× | 8.1% | 0.0× | n/a |
| Ikonisys SA · EURONEXT:ALIKO | US$26.75M | US$31.11M | n/a | 20.4× | n/a | 1.3× | −302.8% | 0.3× | n/a |
| Interpace Biosciences, Inc. · OTC:IDXG | US$26.56M | US$23.63M | 1.2× | 0.6× | 21.0× | 1.1× | 58.1% | 0.0× | -0.33 |
| Microbix Biosystems Inc. · TSX:MBX | US$26.27M | US$25.96M | n/a | 2.4× | n/a | 1.6× | −31.7% | 0.3× | 0.03 |
| Bioptic Inc. · TPEX:6850 | US$26.10M | US$22.55M | n/a | n/a | n/a | 2.0× | n/a | 0.2× | n/a |
| genOway SA · EURONEXT:ALGEN | US$25.86M | US$38.95M | 25.4× | 1.7× | 8.7× | 1.1× | 4.4% | 0.7× | n/a |
| Genesystem Co., Ltd. · KRX:363250 | US$24.68M | US$22.48M | n/a | 29.8× | n/a | 2.8× | n/a | 0.2× | n/a |
| Clever Culture Systems Limited · ASX:CC5 | US$24.56M | US$25.41M | n/a | 8.3× | n/a | 4.9× | −48.4% | 0.4× | n/a |
| CLEO Diagnostics Ltd · ASX:COV | US$24.50M | US$20.38M | n/a | n/a | n/a | 7.4× | n/a | 0.0× | n/a |
| C&R Research Inc. · KRX:359090 | US$24.01M | US$12.51M | 19.3× | 0.3× | 23.4× | 0.7× | 2.6% | 0.0× | n/a |
| HLB Panagene Co. Ltd. · KRX:046210 | US$23.69M | US$6.19M | n/a | 0.6× | n/a | 0.4× | −22.3% | 0.0× | n/a |
| Median of the others | US$25.27M | US$23.09M | 19.3× | 2.0× | 21.0× | 1.4× | −22.3% | 0.2× | -0.15 |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q4 2024 | Jun 27, 2024 · Before open | −1.9% |
| Q3 2023 | Feb 13, 2023 · After close | −0.3% |
Financials
Annual, in KRW
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.8B | 29.4B | 28.0B | 28.8B | 26.3B | 52.0B | 37.7B | 30.4B | 121.2B | 109.0B |
| Cost of revenue | 24.6B | 22.2B | 18.4B | 19.0B | 17.3B | 32.8B | 30.5B | 27.4B | 106.3B | 100.6B |
| Gross profit | 5.18B | 7.20B | 9.58B | 9.82B | 9.01B | 19.2B | 7.20B | 3.01B | 14.9B | 8.37B |
| Research and development | 732.6M | 1.00B | 1.95B | 1.80B | 2.59B | 2.65B | 1.41B | 655.3M | 2.00B | 1.16B |
| Selling, general and administrative | 3.39B | 3.86B | 3.79B | 3.01B | 2.50B | 3.49B | 4.84B | 6.40B | 6.64B | 6.36B |
| Operating income | -4.13B | -3.08B | 4.45B | 3.47B | -3.78B | 2.31B | -11.2B | -9.23B | -6.56B | -9.29B |
| Depreciation and amortization | 2.20B | 1.95B | 2.68B | 3.09B | 3.93B | 4.69B | 4.92B | 8.08B | 7.30B | 6.66B |
| EBITDA | -1.93B | -1.12B | 7.14B | 6.56B | 144.8M | 7.00B | -6.33B | -1.16B | 733.5M | -2.62B |
| Interest expense | 128.4M | 220.3M | 56.9M | 252.3M | 432.9M | 559.7M | 439.3M | 3.44B | 0 | 0 |
| Income before tax | -4.57B | -13.2B | 12.9B | -12.6B | -3.36B | -15.3B | -11.6B | -13.2B | -16.2B | -22.8B |
| Income tax | -34.4M | -150.8M | 0 | 2.07B | ||||||
| Net income | -4.57B | -13.2B | 12.9B | -12.4B | 34.2B | -15.3B | -10.9B | -19.5B | -13.9B | -19.1B |
| Earnings per share, basic | -77.02 | -222.57 | 217.11 | -209.56 | 288.43 | -128.84 | -106.90 | -191.61 | -183.84 | -256.89 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 5.83B | 6.53B | 6.11B | 5.93B | 30.0B | 10.9B | 2.35B | 9.17B | 24.4B | 19.0B |
| Short-term investments | 26.9B | 26.0B | 35.1B | 29.5B | 29.1B | 800.0M | 801.0M | 901.5M | 12.6B | 2.02B |
| Receivables | 6.57B | 5.59B | 5.63B | 4.87B | 4.75B | 9.42B | 10.9B | 7.12B | 23.3B | 20.9B |
| Inventory | 2.44B | 4.20B | 3.65B | 5.24B | 4.35B | 5.93B | 8.10B | 10.0B | 31.3B | 28.6B |
| Current assets | 44.0B | 47.4B | 59.0B | 49.2B | 70.5B | 29.1B | 22.2B | 32.3B | 95.9B | 77.3B |
| Property, plant and equipment | 31.3B | 40.2B | 41.7B | 61.9B | 54.9B | |||||
| Goodwill | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K | 7.99B | 10.1B |
| Total assets | 81.6B | 84.8B | 97.0B | 81.1B | 105.0B | 71.5B | 72.1B | 84.1B | 190.0B | 172.6B |
| Accounts payable | 633.5M | 576.2M | 609.8M | 503.1M | 768.6M | 760.0M | 837.4M | 639.2M | 11.4B | 10.4B |
| Current liabilities | 5.62B | 4.21B | 4.21B | 3.89B | 13.6B | 15.2B | 11.4B | 14.9B | 90.5B | 56.7B |
| Long-term debt | 1.23B | 1.54B | 48.9M | 12.2B | 10.4B | |||||
| Total debt | 7.40B | 8.11B | 7.22B | 8.25B | 64.1B | 51.7B | ||||
| Total liabilities | 13.1B | 12.9B | 11.9B | 9.66B | 21.8B | 23.0B | 20.1B | 21.4B | 110.1B | 74.7B |
| Shareholders' equity | 68.5B | 71.8B | 85.1B | 71.4B | 83.2B | 48.5B | 52.0B | 64.8B | 52.7B | 70.3B |
| Shares outstanding | 59.3M | 59.3M | 59.3M | 59.3M | 118.6M | 118.6M | 101.8M | 101.8M | 75.4M | 74.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 2.60B | 752.3M | 3.76B | 1.16B | 2.35B | 8.74B | -3.90B | -11.5B | -1.97B | -5.11B |
| Capital spending | -2.05B | -4.79B | -925.3M | -485.6M | -2.21B | -256.2M | -742.9M | -16.1B | -2.99B | -5.28B |
| Free cash flow | 546.4M | -4.04B | 2.83B | 674.3M | 140.5M | 8.48B | -6.55B | -30.0B | -5.56B | -10.4B |
| Cash from investing | -4.03B | -347.3M | -26.7B | -26.5B | -5.10B | |||||
| Cash from financing | 3.87B | -2.58B | 23.0B | 33.9B | 20.8B | |||||
| Share buybacks | -10.0M | 9.58M | 9.58M | |||||||
| Change in cash | -699.6M | 422.9M | 174.7M | -24.1B | 19.1B | 8.59B | -6.82B | -15.3B | 5.43B | 10.6B |
Cap table
Built by 6ix from Orientbio, Inc.’s releases
- Common shares
- 29,645,751
- Fully diluted
- 29,645,751
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 29,645,751 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 29,645,751 |
Log in to ask 6ix AI your own questions about Orientbio, Inc.